A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFS |
Texto Completo: | https://ri.ufs.br/handle/riufs/3718 |
Resumo: | Pulmonary circulation is a high flow, low resistance, and low pressure system. Several pathologies, including mitral stenosis, may elevate the impedance of this blood circuit and lead to a pulmonary arterial hypertension. Such syndrome is usually related to a high morbity and patient s death may occur because of the ischemic failure of right ventricle. The use of systemic vasodilating drugs to treat this syndrome is limited by the simultaneous systemic arterial hypotension they often produce. More selective agents to the pulmonary vasculature, such as synthetic analogs of prostacyclin, endothelin receptor inhibitors, and phosphodiesterase III inhibitors, have been choosen for medium and long-term treatment. Unfortunately, the most selective pulmonary hypotensive agent, the inhaled nitric oxide, which is used for short-term treatment, requires special and costly equipment for its administration, making it inaccessible to many hospitals. Furthermore, some degree of toxicity was associated with that substance. The lack of an ideal substance that simultaneously shows pulmonary selectivity, atoxicity, easy handling, accessibility and low cost, motivated the present study to test the effects of clonidine on pulmonary circulation. Clonidine is an alfa-2 adrenergic agonist. It promotes a systemic cardiocirculatory balance by modulating the adrenergic discharge at both central and peripheral levels. When used in clinical doses it presents no toxicity. Furthermore, it is easy to handle, accessible, and inexpensive. However, little has been reported about its pulmonary effect. Therefore, this work aimed to evaluate the effects of clonidine on the pulmonary arterial pressure, on the hemodynamics parameters concerned to the pulmonary circulatory system, as well as on the right ventricular function. At the same time, the action of clonidine on the systemic hemodynamics, cardiac rate, cardiac index and stroke index was also evaluated. This investigation took into account the degree of selectivity of this agent to the pulmonary vessels as well as the presence of a biphasic effect on the pulmonary arterial pressure. This effect has been largely reported on the vascular periferal system. The present research was performed as a prospective clinical trial developed on a group of 16 patients with pulmonary hypertension caused by mitral stenosis of rheumatic origin. Data were obtained before the anesthetic induction, but under the patient sedation. During the control phase, the variations of hemodynamic parameters under the action of a placebo were evaluated. During the test phase, the behavior of these parameters was evaluated under the clonidine effect. The time schedule for data measurements was the following: T0 (initial control); T1 (10 minutes after placebo administration); T2 (20 minutes after placebo administration); T3 (10 minutes after clonidine administration); T4 (20 minutes after clonidine administration). T2 was used as the control time to study the clonidine effects. Statistical analysis showed that during the control phase the variables remained unchanged, but under the effect of clonidine there was a significant reduction of the mean values concerned to the following parameters: pulmonary arterial mean pressure (27.1%) and systemic arterial mean pressure (20%), pulmonary vascular resistance index (34%) and systemic vascular resistance index (14.6%), right and left ventricular systolic work indexes (19.9% and 10%, respectively), right atrium pressure (11.5%), pulmonary arterial wedge pressure (21.5%), heart rate and cardiac index (15.8% and 7.9%, respectively). Besides that, a significant increase of the stroke index (10.2%) occured. The biphasic effect on the sistemic arterial pressure occured in 50% of the studied patients, whereas the same effect on the pulmonary arterial pressure was observed in 20% of the same sample. Clonidine also exerted a moderately selective action on the pulmonary circulation, demonstrated through the reduction of the relationship between mean value of the pulmonary vascular resistance index and mean value of the systemic vascular resistance index evaluated at the times T2 and T3. |
id |
UFS-2_866dc7bac3e6aaf458dcd6a5323acf64 |
---|---|
oai_identifier_str |
oai:ufs.br:riufs/3718 |
network_acronym_str |
UFS-2 |
network_name_str |
Repositório Institucional da UFS |
repository_id_str |
|
spelling |
Garcia, Maria Helena Domingueshttp://lattes.cnpq.br/2843929626352861Melo, Valdinaldo Aragão dehttp://lattes.cnpq.br/67349582113969292017-09-26T12:16:52Z2017-09-26T12:16:52Z2005-09-29GARCIA, Maria Helena Domingues. A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral. 2005. 138 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Sergipe, Aracaju, 2005.https://ri.ufs.br/handle/riufs/3718Pulmonary circulation is a high flow, low resistance, and low pressure system. Several pathologies, including mitral stenosis, may elevate the impedance of this blood circuit and lead to a pulmonary arterial hypertension. Such syndrome is usually related to a high morbity and patient s death may occur because of the ischemic failure of right ventricle. The use of systemic vasodilating drugs to treat this syndrome is limited by the simultaneous systemic arterial hypotension they often produce. More selective agents to the pulmonary vasculature, such as synthetic analogs of prostacyclin, endothelin receptor inhibitors, and phosphodiesterase III inhibitors, have been choosen for medium and long-term treatment. Unfortunately, the most selective pulmonary hypotensive agent, the inhaled nitric oxide, which is used for short-term treatment, requires special and costly equipment for its administration, making it inaccessible to many hospitals. Furthermore, some degree of toxicity was associated with that substance. The lack of an ideal substance that simultaneously shows pulmonary selectivity, atoxicity, easy handling, accessibility and low cost, motivated the present study to test the effects of clonidine on pulmonary circulation. Clonidine is an alfa-2 adrenergic agonist. It promotes a systemic cardiocirculatory balance by modulating the adrenergic discharge at both central and peripheral levels. When used in clinical doses it presents no toxicity. Furthermore, it is easy to handle, accessible, and inexpensive. However, little has been reported about its pulmonary effect. Therefore, this work aimed to evaluate the effects of clonidine on the pulmonary arterial pressure, on the hemodynamics parameters concerned to the pulmonary circulatory system, as well as on the right ventricular function. At the same time, the action of clonidine on the systemic hemodynamics, cardiac rate, cardiac index and stroke index was also evaluated. This investigation took into account the degree of selectivity of this agent to the pulmonary vessels as well as the presence of a biphasic effect on the pulmonary arterial pressure. This effect has been largely reported on the vascular periferal system. The present research was performed as a prospective clinical trial developed on a group of 16 patients with pulmonary hypertension caused by mitral stenosis of rheumatic origin. Data were obtained before the anesthetic induction, but under the patient sedation. During the control phase, the variations of hemodynamic parameters under the action of a placebo were evaluated. During the test phase, the behavior of these parameters was evaluated under the clonidine effect. The time schedule for data measurements was the following: T0 (initial control); T1 (10 minutes after placebo administration); T2 (20 minutes after placebo administration); T3 (10 minutes after clonidine administration); T4 (20 minutes after clonidine administration). T2 was used as the control time to study the clonidine effects. Statistical analysis showed that during the control phase the variables remained unchanged, but under the effect of clonidine there was a significant reduction of the mean values concerned to the following parameters: pulmonary arterial mean pressure (27.1%) and systemic arterial mean pressure (20%), pulmonary vascular resistance index (34%) and systemic vascular resistance index (14.6%), right and left ventricular systolic work indexes (19.9% and 10%, respectively), right atrium pressure (11.5%), pulmonary arterial wedge pressure (21.5%), heart rate and cardiac index (15.8% and 7.9%, respectively). Besides that, a significant increase of the stroke index (10.2%) occured. The biphasic effect on the sistemic arterial pressure occured in 50% of the studied patients, whereas the same effect on the pulmonary arterial pressure was observed in 20% of the same sample. Clonidine also exerted a moderately selective action on the pulmonary circulation, demonstrated through the reduction of the relationship between mean value of the pulmonary vascular resistance index and mean value of the systemic vascular resistance index evaluated at the times T2 and T3.A circulação pulmonar é um sistema de alto fluxo, baixa resistência e baixa pressão. Patologias diversas, dentre elas a estenose mitral, podem elevar a impedância desse circuito, desencadeando a síndrome de hipertensão arterial pulmonar. Esta cursa com elevada morbidade, podendo levar ao óbito pela falência isquêmica do ventrículo direito. A utilização de drogas vasodilatadoras periféricas no tratamento dessa síndrome ficou limitada pela simultânea hipotensão arterial sistêmica que provoca. Agentes mais seletivos sobre a vasculatura pulmonar, como os análogos sintéticos da prostaciclina, os inibidores dos receptores de endotelina e os inibidores da fosfodiesterase III, têm sido as drogas de eleição para o tratamento de médio e de longo prazo. O mais seletivo dos agentes hipotensores pulmonares, o óxido nítrico inalado, aplicado ao tratamento de curto prazo, exige equipamento especial e oneroso para a sua administração, tornando-o inacessível a muitos nosocômios. Paralelamente, possui potencial toxicidade. A inexistência de um fármaco ideal que apresente, simultaneamente, seletividade sobre a pequena circulação, atoxicidade, fácil manuseio e disponibilidade, além de ser pouco oneroso, conduziu ao estudo da clonidina sobre a árvore circulatória pulmonar. Este agente terapêutico é um agonista alfa-2 adrenérgico, com efeitos favoráveis reconhecidos sobre o equilíbrio circulatório sistêmico por modular a descarga adrenérgica em níveis central e periférico. É atóxico quando utilizado em doses clínicas. Além disso, oferece fácil manuseio, boa acessibilidade e baixo custo. Os estudos a respeito da sua ação pulmonar são escassos. Assim, a presente investigação teve como objetivo avaliar os efeitos da clonidina sobre a pressão arterial pulmonar, sobre os demais parâmetros hemodinâmicos da pequena circulação e sobre a função ventricular direita. Paralelamente, analisou as ações sobre a hemodinâmica sistêmica, a freqüência cardíaca, o índice cardíaco e o índice de ejeção. Foi também investigado o grau de seletividade pulmonar desse agente, bem como a presença de um efeito bifásico sobre a pressão arterial pulmonar, pois este efeito tem sido amplamente relatado no sistema vascular periférico. Para a execução dos objetivos propostos, um ensaio clínico prospectivo, realizado antes da indução anestésica, mas sob sedação, foi desenvolvido num grupo de 16 pacientes, todos portadores de hipertensão pulmonar resultante de estenose mitral de origem reumática. Durante a fase controle foram analisadas as variações dos parâmetros hemodinâmicos sob a ação de um placebo. Durante a fase teste foi avaliado o comportamento dos mesmos parâmetros sob a ação da clonidina. A padronização dos tempos nos quais se fez a coleta de dados foi a seguinte: T0 (controle inicial); T1 (10 min após a administração do placebo); T2 (20 min após o placebo); T3 (10 min após a administração da clonidina); T4 (20 min após a clonidina). A análise estatística dos resultados demonstrou não haver alteração das variáveis estudadas durante a fase controle. Todavia, sob o efeito da clonidina houve variações estatisticamente significantes dos mesmos parâmetros nos seus valores médios: redução da pressão arterial pulmonar média (27,1%) e da pressão arterial sistêmica média (20%), dos índices de resistência vascular pulmonar (34%) e sistêmica (14,6%), dos índices de trabalho sistólico dos ventrículos direito (19,9%) e esquerdo (10%), da pressão do átrio direito (11,5%), da pressão de oclusão da artéria pulmonar (21,5%), da freqüência cardíaca (15,8%) e do índice cardíaco (7,9%), ao lado de uma elevação significante do índice de ejeção (10,2%). O efeito bifásico sobre a pressão arterial sistêmica ficou evidente em 50% dos pacientes estudados, enquanto que o mesmo efeito sobre a pressão arterial pulmonar ocorreu em 20% da amostra estudada. A clonidina também exerceu uma ação moderadamente seletiva sobre a circulação pulmonar, demonstrada através da diminuição do quociente obtido entre o valor médio do índice de resistência vascular pulmonar e valor médio do índice de resistência vascular sistêmica, ambos avaliados nos tempos T2 e T3.application/pdfporUniversidade Federal de SergipePós-Graduação em Ciências da SaúdeUFSBRClonidinaBloqueadores alfa-2 adrenérgicosHipertensão pulmonarEstenose mitralCirculação pulmonarHipotensores pulmonaresClonidineAlpha-2 adrenergic blockersPulmonary hypertensionMitral stenosisPulmonary circulationPulmonary hypotensive agentsCNPQ::CIENCIAS DA SAUDEA clonidina reduz a pressão arterial pulmonar em portadores de estenose mitralinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSTEXTMARIA_HELENA_DOMINGUES_GARCIA.pdf.txtMARIA_HELENA_DOMINGUES_GARCIA.pdf.txtExtracted texttext/plain216634https://ri.ufs.br/jspui/bitstream/riufs/3718/2/MARIA_HELENA_DOMINGUES_GARCIA.pdf.txt4f27f81faa32c888a945091be5a379e8MD52THUMBNAILMARIA_HELENA_DOMINGUES_GARCIA.pdf.jpgMARIA_HELENA_DOMINGUES_GARCIA.pdf.jpgGenerated Thumbnailimage/jpeg1344https://ri.ufs.br/jspui/bitstream/riufs/3718/3/MARIA_HELENA_DOMINGUES_GARCIA.pdf.jpgc7da8ed68c4e7713daabefd433f958eeMD53ORIGINALMARIA_HELENA_DOMINGUES_GARCIA.pdfapplication/pdf975990https://ri.ufs.br/jspui/bitstream/riufs/3718/1/MARIA_HELENA_DOMINGUES_GARCIA.pdf81cede13668850d47d9d62eefc64a2e5MD51riufs/37182017-11-28 16:21:52.477oai:ufs.br:riufs/3718Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2017-11-28T19:21:52Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false |
dc.title.por.fl_str_mv |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
title |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
spellingShingle |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral Garcia, Maria Helena Domingues Clonidina Bloqueadores alfa-2 adrenérgicos Hipertensão pulmonar Estenose mitral Circulação pulmonar Hipotensores pulmonares Clonidine Alpha-2 adrenergic blockers Pulmonary hypertension Mitral stenosis Pulmonary circulation Pulmonary hypotensive agents CNPQ::CIENCIAS DA SAUDE |
title_short |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
title_full |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
title_fullStr |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
title_full_unstemmed |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
title_sort |
A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral |
author |
Garcia, Maria Helena Domingues |
author_facet |
Garcia, Maria Helena Domingues |
author_role |
author |
dc.contributor.author.fl_str_mv |
Garcia, Maria Helena Domingues |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/2843929626352861 |
dc.contributor.advisor1.fl_str_mv |
Melo, Valdinaldo Aragão de |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/6734958211396929 |
contributor_str_mv |
Melo, Valdinaldo Aragão de |
dc.subject.por.fl_str_mv |
Clonidina Bloqueadores alfa-2 adrenérgicos Hipertensão pulmonar Estenose mitral Circulação pulmonar Hipotensores pulmonares |
topic |
Clonidina Bloqueadores alfa-2 adrenérgicos Hipertensão pulmonar Estenose mitral Circulação pulmonar Hipotensores pulmonares Clonidine Alpha-2 adrenergic blockers Pulmonary hypertension Mitral stenosis Pulmonary circulation Pulmonary hypotensive agents CNPQ::CIENCIAS DA SAUDE |
dc.subject.eng.fl_str_mv |
Clonidine Alpha-2 adrenergic blockers Pulmonary hypertension Mitral stenosis Pulmonary circulation Pulmonary hypotensive agents |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE |
description |
Pulmonary circulation is a high flow, low resistance, and low pressure system. Several pathologies, including mitral stenosis, may elevate the impedance of this blood circuit and lead to a pulmonary arterial hypertension. Such syndrome is usually related to a high morbity and patient s death may occur because of the ischemic failure of right ventricle. The use of systemic vasodilating drugs to treat this syndrome is limited by the simultaneous systemic arterial hypotension they often produce. More selective agents to the pulmonary vasculature, such as synthetic analogs of prostacyclin, endothelin receptor inhibitors, and phosphodiesterase III inhibitors, have been choosen for medium and long-term treatment. Unfortunately, the most selective pulmonary hypotensive agent, the inhaled nitric oxide, which is used for short-term treatment, requires special and costly equipment for its administration, making it inaccessible to many hospitals. Furthermore, some degree of toxicity was associated with that substance. The lack of an ideal substance that simultaneously shows pulmonary selectivity, atoxicity, easy handling, accessibility and low cost, motivated the present study to test the effects of clonidine on pulmonary circulation. Clonidine is an alfa-2 adrenergic agonist. It promotes a systemic cardiocirculatory balance by modulating the adrenergic discharge at both central and peripheral levels. When used in clinical doses it presents no toxicity. Furthermore, it is easy to handle, accessible, and inexpensive. However, little has been reported about its pulmonary effect. Therefore, this work aimed to evaluate the effects of clonidine on the pulmonary arterial pressure, on the hemodynamics parameters concerned to the pulmonary circulatory system, as well as on the right ventricular function. At the same time, the action of clonidine on the systemic hemodynamics, cardiac rate, cardiac index and stroke index was also evaluated. This investigation took into account the degree of selectivity of this agent to the pulmonary vessels as well as the presence of a biphasic effect on the pulmonary arterial pressure. This effect has been largely reported on the vascular periferal system. The present research was performed as a prospective clinical trial developed on a group of 16 patients with pulmonary hypertension caused by mitral stenosis of rheumatic origin. Data were obtained before the anesthetic induction, but under the patient sedation. During the control phase, the variations of hemodynamic parameters under the action of a placebo were evaluated. During the test phase, the behavior of these parameters was evaluated under the clonidine effect. The time schedule for data measurements was the following: T0 (initial control); T1 (10 minutes after placebo administration); T2 (20 minutes after placebo administration); T3 (10 minutes after clonidine administration); T4 (20 minutes after clonidine administration). T2 was used as the control time to study the clonidine effects. Statistical analysis showed that during the control phase the variables remained unchanged, but under the effect of clonidine there was a significant reduction of the mean values concerned to the following parameters: pulmonary arterial mean pressure (27.1%) and systemic arterial mean pressure (20%), pulmonary vascular resistance index (34%) and systemic vascular resistance index (14.6%), right and left ventricular systolic work indexes (19.9% and 10%, respectively), right atrium pressure (11.5%), pulmonary arterial wedge pressure (21.5%), heart rate and cardiac index (15.8% and 7.9%, respectively). Besides that, a significant increase of the stroke index (10.2%) occured. The biphasic effect on the sistemic arterial pressure occured in 50% of the studied patients, whereas the same effect on the pulmonary arterial pressure was observed in 20% of the same sample. Clonidine also exerted a moderately selective action on the pulmonary circulation, demonstrated through the reduction of the relationship between mean value of the pulmonary vascular resistance index and mean value of the systemic vascular resistance index evaluated at the times T2 and T3. |
publishDate |
2005 |
dc.date.issued.fl_str_mv |
2005-09-29 |
dc.date.accessioned.fl_str_mv |
2017-09-26T12:16:52Z |
dc.date.available.fl_str_mv |
2017-09-26T12:16:52Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
GARCIA, Maria Helena Domingues. A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral. 2005. 138 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Sergipe, Aracaju, 2005. |
dc.identifier.uri.fl_str_mv |
https://ri.ufs.br/handle/riufs/3718 |
identifier_str_mv |
GARCIA, Maria Helena Domingues. A clonidina reduz a pressão arterial pulmonar em portadores de estenose mitral. 2005. 138 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Sergipe, Aracaju, 2005. |
url |
https://ri.ufs.br/handle/riufs/3718 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Sergipe |
dc.publisher.program.fl_str_mv |
Pós-Graduação em Ciências da Saúde |
dc.publisher.initials.fl_str_mv |
UFS |
dc.publisher.country.fl_str_mv |
BR |
publisher.none.fl_str_mv |
Universidade Federal de Sergipe |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFS instname:Universidade Federal de Sergipe (UFS) instacron:UFS |
instname_str |
Universidade Federal de Sergipe (UFS) |
instacron_str |
UFS |
institution |
UFS |
reponame_str |
Repositório Institucional da UFS |
collection |
Repositório Institucional da UFS |
bitstream.url.fl_str_mv |
https://ri.ufs.br/jspui/bitstream/riufs/3718/2/MARIA_HELENA_DOMINGUES_GARCIA.pdf.txt https://ri.ufs.br/jspui/bitstream/riufs/3718/3/MARIA_HELENA_DOMINGUES_GARCIA.pdf.jpg https://ri.ufs.br/jspui/bitstream/riufs/3718/1/MARIA_HELENA_DOMINGUES_GARCIA.pdf |
bitstream.checksum.fl_str_mv |
4f27f81faa32c888a945091be5a379e8 c7da8ed68c4e7713daabefd433f958ee 81cede13668850d47d9d62eefc64a2e5 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS) |
repository.mail.fl_str_mv |
repositorio@academico.ufs.br |
_version_ |
1802110740004339712 |